The immune system has a biological telecommunications system—small proteins known as interleukins that send signals among the leukocyte white blood cells to control their defense against infections or ...
On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared at ...
Adam Broerman, a graduate student in the University of Washington’s Institute for Protein Design, studies an engineered protein that can turn off protein interactions. (IPD Photo / Ian Haydon) The ...
A targeted delivery system boosts the numbers of anti-inflammatory immune cells within the brain to restrict brain inflammation and damage. This therapeutic method, which delivers interleukin 2 to the ...
BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, ...
Real-life use of cabozantinib as front-line therapy in metastatic renal cell carcinoma: The CabFRONT (Meet-URO 24) study. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in subjects with solid tumors. Background: High-dose interleukin-2 (IL-2) has been approved in metastatic renal ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard treatment for amyotrophic lateral sclerosis slowed functional decline and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results